Mediterr J Rheumatol 2017;28(4):201-5
Current and future trends in Russian Rheumatology Care and Research
Authors Information
Immunology and Molecular Biology Laboratory, Nasonova Research Institute of Rheumatology, Moscow, Russia
  1. Widdifield J, Paterson J M, Bernatsky S, Tu K, Tomlinson G, Kuriya B, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheumatol 2014;66:786-93.
  2. Bombardier C, Hawker G, Mosher D, for the Arthritis Alliance of Canada. The impact of arthritis in Canada: today and over the next 30 years; 2011. http://www.arthritisalliance.ca/docs/20111022_2200_impact_of_arthritis.pdf.
  3. Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013;80:29–33.
  4. Nasonov E L. Rheumatology in Russia in the 21st century. Ter Arkh 2013;85:4-7. (In Russian).
  5. Folomeeva O M, Galushko E A, Erdes S F. Prevalence of rheumatic diseases in adult populations of Russian Federation and the USA. Nauchno-Prakticheskaya Revmatologiya 2008;46:4-13. (In Russian).
  6. Balabanova R M, Erdes S F. Rheumatic diseases in the adult population in federal districts of Russia. Nauchno-Prakticheskaya Revmatologiya 2014;52:5-7. (In Russian). 
  7. Orlova E V, Karateev D E, Amirdjanova D Y. Efficacy of the individual rehabilitation program for rheumatoid arthritis patients. Nauchno-Prakticheskaya Revmatologiya 2012;50:45-53. (In Russian).
  8. van Nies J A, Krabben A, Schoones J W, Huizinga T W, Kloppenburg M, van der Helm-van Mil A H. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014;73:861-70.
  9. Moreland L W, O'Dell J R, Paulus H E, Curtis J R, Bathon J M, St Clair E W, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35.
  10. Cutolo M, Spies C M, Buttgereit F, Paolino S, Pizzorni C. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. Arthritis Res Ther 2014;16 Suppl 2:S1.
  11. Goodman S M, Cronstein B N, Bykerk V P. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol 2015;33:272-8.
  12. Nasonov E L. Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations. Ter Arkh 2016;88:4-10. (In Russian).
  13. Castañeda-Hernández G, Szekanecz Z, Mysler E, Azevedo V F, Guzman R, Gutierrez M, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 2014;81:471-7.
  14. Nasonov E L, Karateev D E, Satybaldyev A M, Luchikhina E L, Lukina G V, Nikolenko M V, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya 2015;53:472-84. (In Russian).
  15. Ermakova Y A, Karateev D E, Luchikhina E L, Demidova N V. Trends in disease activity, functional status, and radiographic changes in early rheumatoid arthritis: Results of a 5-year follow-up within the Russian RADICAL program. Nauchno-Prakticheskaya Revmatologiya 2015;53:17-23. (In Russian).
  16. Pchelintseva A O, Panasyuk E Y, Ryabitseva. Efficacy of etanercept in patients with rheumatoid arthritis (results of the Russian multicenter ETALON Study). Nauchno-Prakticheskaya Revmatologiya 2013; 51:639-45. (In Russian).
  17. Karateev D E, Luchikhina E L, Demidova N V, Gridneva G S, Kanonirova M A, Muraviev Y V, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trail): results of 12-month treatment in 130 patients. Nauchno-Prakticheskaya Revmatologiya 2014;52:607-14. (In Russian).
  18. Nasonov EL. Methotrexate in rheumatoid arthritis in 2015: new facts and ideas. Nauchno-Prakticheskaya Revmatologiya 2015;53:421-33. (In Russian).
  19. Orlova E V, Karateev D E, Bulgakova N A. Treating rheumatoid arthritis to target: Russian version of international guidelines for patients. Nauchno-Prakticheskaya Revmatologiya 2013;51:246-54. (In Russian).
  20. Nasonov E L, Zonova E V, Ivanova O N, Knyazeva L A, Mazurov V I, Samigullina RR, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia and MabThera) in rheumatoid arthritis (The BIORA Study). Nauchno-Prakticheskaya Revmatologiya 2016;54:510-9. (In Russian).
  21. Nasonov E L, Mazurov V I, Usacheva Y U, Chernyaeva E V, Ustyugov Y Y, Ulitin A V, et al. Development of Russian original biological agents for the threatment of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya 2017;55:201-10. (In Russian).
  22. Gerhold K, Richter A, Schneider M, Bergerhausen H J, Demary W, Liebhaber A, et al. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology (Oxford) 2015;54:1858-66.
  23. Lygina E V, Pron’kina E V, Yakushin S S. A structured training program for patients with rheumatoid arthritis to self-monitor disease activity. Nauchno-Prakticheskaya Revmatologiya 2014;52:37-43. (In Russian). 
  24. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M L, Tarp U, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther 2016;18:50.
  25. Burska A N, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood L D, et al. Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J 2014; 14:93-106.
  26. Tchetina E V. “High” and “Low” Gene Expression Signatures in Rheumatoid Arthritis: an Emerging Approach for Patient Stratification and Therapy Choice. Int J Orthopaedics 2015;2:219-26.
  27. Tchetina E V, Pivanova A N, Markova A G, Lukina G V, Aleksandrova E N, Aleksankin A P, et al. Rituximab downregulates gene expression associated with cell growth and proliferation, survival, and proteolysis in the peripheral blood of rheumatoid arthritis patients to healthy subject levels: association of high baseline autophagy-related ULK1 expression with improved pain control. Arthritis 2016;2016:4963950.
  28. Tchetina E V, Demidova N V, Karateev D E, Nasonov E L. Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin K gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol 2013;2013:457876.
  29. Tchetina E V, Demidova N V, Markova G A, Taskina E A, Glukhova S I, Karateev D E. Increased baseline RUNX 2, caspase 3, and p21 gene expressions in the peripheral blood of naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy. Int J Rheum Dis 2017;20:1468–80.
  30. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2013;39:1-19.
  31. Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56.
  32. Sun B H, Wu C W, Kalunian K C. New developments in osteoarthritis. Rheum Dis Clin North Am 2007;33:135-48.
  33. Pereira D, Peleteiro B, Araújo J, Branco J, Santos R A, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011;19:1270-85.
  34. Tchetina E V, Squires G, Poole A R. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol 2005;32:876-86.
  35. Tchetina E V, Kobayashi M, Yasuda T, Meijers T, Pidoux I, Poole A R. Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. Matrix Biol 2007;26:247-58.
  36. Cicuttini F M, Wluka A E. Osteoarthritis: Is OA a mechanical or systemic disease? Nat Rev Rheumatol 2014;10:515-6.
  37. Berenbaum F, Griffin T M, Liu-Bryan R. Review: Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheumatol 2017;69:9-21.
  38. Monira Hussain S, Wang Y, Cicuttini F M, Simpson J A, Giles G G, Graves S, et al. Incidence of total knee and hip replacement for osteoarthritis in relation to the metabolic syndrome and its components: a prospective cohort study. Semin Arthritis Rheum 2014;43:429-36.
  39. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage 2015;23:1955-65.
  40. Solon-Biet S M, Mitchell S J, de Cabo R, Raubenheimer D, Le Couteur D G, Simpson S J. Macronutrients and caloric intake in health and longevity. J Endocrinol 2015;226:R17-28.
  41. Tchetina E V, Markova G A, Poole A R, Zukor D J, Antoniou J, Makarov S A, Kuzin A N. Deferoxamine suppresses collagen cleavage, protease, cytokine, COL10A1 expression and upregulates AMPK and Krebs cycle genes in human osteoarthritic cartilage. Int J Rheumatol 2016;2016:6432867.
  42. Tchetina E V, Poole A R, Zaitseva E M, Sharapova E P, Kashevarova N G, Taskina E A, et al. Differences in Mammalian target of rapamycin gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis 2013;2013:461486.